Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 72

Sort by

Sort Order Select

Journal Articles

Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in the Patients with CCAAT Enhancer-Binding Protein a Gene (CEBPA) Mutated Acute Myeloid Leukemia

Swe Mar Linn, Nihar Desai, Steven M. Chan, Andre C. Schuh, Aniket Banker, Marta Beata Davidson, Guillaume Richard-Carpentier, Aron Shimmer, Dawn C. Maze, Karen Yee, Mark D. Minden, Vikas Gupta, Tracy Stockley, Hassan Sibai, Jose-Mario Capo-Chichi, Anne Maria Tierens, Dennis Dong Hwan Kim

Blood (2024) 144 (Supplement 1): 1570.

https://doi.org/10.1182/blood-2024-211434

Published: 2024

Journal Articles

Single-Cell Proteogenomic Analysis of Clonal Evolution in Patient-Derived Xenograft Models of AML Treated with IDH Inhibitors

Alex Liu, Severine Cathelin, Yitong Yang, Farzaneh Aboualizadeh, Amina Abow, Gurbaksh Basi, Lance Li, David L Dai, Abdula Maher, Eric Grignano, Mohsen Hosseini, Dhanoop Manikoth Ayyathan, Vivian Wang, Troy Ketela, Dylan Marchione, Adriana Tron, Andrea Arruda, Mark D. Minden, Steven M. Chan

Blood (2024) 144 (Supplement 1): 4995.

https://doi.org/10.1182/blood-2024-211634

Published: 2024

Journal Articles

What Is the Prognostic Relevance of Responses Less Than a CR(Sub-CR) to Initial AML Treatment?

Akhil Rajendra, Elliot Smith, Eshetu Atenafu, Aniket Bankar, Steven M. Chan, Marta Beata Davidson, Vikas Gupta, Mark D. Minden, Maria Agustina Perusini, Guillaume Richard-Carpentier, Aaron D Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Dawn C. Maze

Blood (2024) 144 (Supplement 1): 5193.

https://doi.org/10.1182/blood-2024-208884

Published: 2024

Journal Articles

Intensive Chemotherapy Vs. Azacitidine + Venetoclax for AML with Secondary Mutations

Elliot Smith, Akhil Rajendra Kurup, Eshetu Atenafu, Aniket Bankar, Steven M. Chan, Marta Beata Davidson, Vikas Gupta, Mark D. Minden, Guillaume Richard-Carpentier, Aaron D Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Dawn C. Maze

Blood (2024) 144 (Supplement 1): 1483.

https://doi.org/10.1182/blood-2024-202069

Published: 2024

Journal Articles

Real-World Experience with CPX-351 for Secondary Acute Myeloid Leukemia: Comparison with FLAG-IDA in a Propensity Score Matching Analysis

Blood (2024) 144 (Supplement 1): 1506.

https://doi.org/10.1182/blood-2024-204004

Published: 2024

Journal Articles

Depletion of CD59 Inhibits the Proliferation and Survival of Acute Myeloid Leukemia Cells By Altering Lipid Raft Composition and Suppression of Raf/MEK/ERK Signaling

Abdula Maher, Severine Cathelin, Dhanoop Manikoth Ayyathan, Yitong Yang, Alex Liu, Mohsen Hosseini, Steven M. Chan

Blood (2024) 144 (Supplement 1): 2719.

https://doi.org/10.1182/blood-2024-210688

Published: 2024

Journal Articles

FLAG-IDA Plus Venetoclax in High-Risk Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia: The Princess Margaret Cancer Center Experience

Eshrak Al-Shaibani, Marta Beata Davidson, Aniket Bankar, Steven M. Chan, Hassan Sibai, Dawn C. Maze, Aaron D Schimmer, Mark D. Minden, Karen Yee, Vikas Gupta, Andre C. Schuh, Guillaume Richard-Carpentier

Blood (2024) 144 (Supplement 1): 4273.

https://doi.org/10.1182/blood-2024-209476

Published: 2024

Journal Articles

Uncovering the Role of CD59 As a Novel Therapeutic Target Against High-Risk Acute Myeloid Leukemia

Abdula Maher, Steven M. Chan

Blood (2023) 142 (Supplement 1): 1376.

https://doi.org/10.1182/blood-2023-191036

Published: 2023

Journal Articles

Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia Patients with FMS3-like Tyrosine Kinase-3 Internal Tandem Duplication (FLT3-ITD)

Josephine Anne Lucero, Aniket Bankar, Marta Beata Davidson, Guillaume Richard-Carpentier, Aaron D. Schimmer, Andre C. Schuh, Dawn C. Maze, Karen Yee, Mark D. Minden, Steven M. Chan, Jonas Mattsson, Rajat Kumar, Vikas Gupta, Jose-Mario Capo-Chichi, Tracy Stockley, Hassan Sibai, Anne Maria Tierens, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 1595.

https://doi.org/10.1182/blood-2023-190694

Published: 2023

Journal Articles

Final Results of the Phase Ib/II Study Evaluating Enasidenib in Combination with Venetoclax in Patients with IDH2 -Mutated Relapsed/Refractory Myeloid Malignancies

Guillaume Richard-Carpentier, Gopila Gupta, Charina Cameron, Severine Cathelin, Aniket Bankar, Marta Beata Davidson, Vikas Gupta, Dawn C. Maze, Mark D. Minden, Tracy Murphy, Aaron D. Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Courtney D. DiNardo, Joseph Brandwein, Caroline Jane McNamara, Steven M. Chan

Blood (2023) 142 (Supplement 1): 159.

https://doi.org/10.1182/blood-2023-188341

Published: 2023

Journal Articles

Somatic TET2 Mutations Prime the Immune System for Response to Immune Checkpoint Blockade

Robert Vanner, Andy G.X. Zeng, Michelle Chan-Seng-Yue, Suraj Bansal, Elisa Donato, Liqing Jin, Sofia Genta, Enrique Sanz Garcia, Steven M. Chan, Andreas Trumpp, John E. Dick

Blood (2023) 142 (Supplement 1): 2689.

https://doi.org/10.1182/blood-2023-177740

Published: 2023

Journal Articles

Outcome of ALL in Adult Patient with Down Syndrome, Single Center Experience

Salman Alharbi, Maria Agustina Perusini, Sita Bhella, Mark D. Minden, Dawn Maze, Vikas Gupta, Aaron D. Schimmer, Andre C. Schuh, Karen Yee, Steven M. Chan, Aniket Bankar, Marta B. Davidson, Guillaume Richard-Carpentier, Jad Sibai, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3187–3188.

https://doi.org/10.1182/blood-2022-168662

Published: 2022

Journal Articles

Thrombopoietin Receptor Signaling Promotes the Competitive Advantage of TET2 -Mutated Hematopoietic Stem and Progenitor Cells in Clonal Hematopoiesis

Yitong Yang, Amit Subedi, Steven M. Chan

Blood (2022) 140 (Supplement 1): 981–982.

https://doi.org/10.1182/blood-2022-162554

Published: 2022

Journal Articles

Metformin Treatment Abrogates the Competitive Advantage of Dnmt3a R878H HSPCs By Enhancing DNA Methylation Activity

Mohsen Hosseini, Severine Cathelin, Alex Liu, Yitong Yang, Amit Subedi, Dhanoop Manikoth Ayyathan, Shraddha Pai, Steven M. Chan

Blood (2022) 140 (Supplement 1): 977–978.

https://doi.org/10.1182/blood-2022-170366

Published: 2022

Journal Articles

Clinical and Biological Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (t-ALL) Following Multiple Myeloma Are Distinct in Comparison to t-ALL Following Other Cancers

Josephine Anne Lucero, Brayan Merchán, Osamah Jamal S. Jarallah, Aniket Bankar, Steven M. Chan, Marta B. Davidson, Vikas Gupta, Dawn Maze, Mark D. Minden, Guillaume Richard-Carpentier, Aaron D. Schimmer, Andre C. Schuh, Karen Yee, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3166–3168.

https://doi.org/10.1182/blood-2022-168488

Published: 2022

Journal Articles

Multiparameter Flow Cytometry-Based Residual Disease Analysis Identifies Intermediate-Risk AML Patients Who May Benefit from Allogeneic Hematopoietic Stem Cell Transplantation

Josephine Anne Lucero, Anne Tierens, Muhned Alhumaid, Jose-Mario Capo-Chichi, Tracy L. Stockley, Vikas Gupta, Steven M. Chan, Andre C. Schuh, Mark D. Minden, Jonas Mattsson, Rajat Kumar, Hassan Sibai, Dennis Dong Hwan Kim

Blood (2022) 140 (Supplement 1): 11797–11798.

https://doi.org/10.1182/blood-2022-168260

Published: 2022

Journal Articles

Acute Lymphoblastic Leukemia in Patients 60 Years and Older Treated with Pediatric-Inspired Protocols, 20 Years of Follow-up

Maria Agustina Perusini, Eshetu G. Atenafu, Aniket Bankar, Vikas Gupta, Mark D. Minden, Jad Sibai, Dawn Maze, Marta B. Davidson, Steven M. Chan, Fernando Binder, Guillaume Richard-Carpentier, Salman Alharbi, Claire Andrews, Karen Yee, Andre C. Schuh, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3176–3177.

https://doi.org/10.1182/blood-2022-170121

Published: 2022

Journal Articles

Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?

Fatima M Khadadah, Claire Andrews, Eshetu G. Atenafu, Andre C. Schuh, Dawn Maze, Karen Yee, Osamah Jamal S. Jarallah, Mark D. Minden, Aaron D. Schimmer, Steven M. Chan, Vikas Gupta, Dennis Dong Hwan Kim, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3169–3171.

https://doi.org/10.1182/blood-2022-169342

Published: 2022

Journal Articles

A Novel Role for PLK1 in Leukemia Stem Cell Function in Acute Myeloid Leukemia

Qiang Liu, Alex Murison, Andy G.X. Zeng, Changjiang Xu, Veronique Voisin, Faith Yeung, Amit Subedi, Steven M. Chan, Brian Raught, Gary D Bader, John E. Dick, Jean C.Y. Wang

Blood (2022) 140 (Supplement 1): 5920–5921.

https://doi.org/10.1182/blood-2022-169732

Published: 2022

Journal Articles

Single Centre, Retrospective Analysis of Treatment Outcomes and Prognostic Factors in Blastic Phase Chronic Myeloid Leukemia (CML-BP) Following Systemic Therapy

Kenny Tang, Dawn Maze, Karen Yee, Hassan Sibai, Marta B. Davidson, Steven M. Chan, Aaron D. Schimmer, Andre C. Schuh, Aniket Bankar, Guillaume Richard-Carpentier, Anne Tierens, Mark D. Minden, Vikas Gupta, Jeffrey H. Lipton, Dennis Kim

Blood (2022) 140 (Supplement 1): 9608–9610.

https://doi.org/10.1182/blood-2022-166416

Published: 2022

NARROW

Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in the Patients with CCAAT Enhancer-Binding Protein a Gene (CEBPA) Mutated Acute Myeloid Leukemia

Single-Cell Proteogenomic Analysis of Clonal Evolution in Patient-Derived Xenograft Models of AML Treated with IDH Inhibitors

What Is the Prognostic Relevance of Responses Less Than a CR(Sub-CR) to Initial AML Treatment?

Intensive Chemotherapy Vs. Azacitidine + Venetoclax for AML with Secondary Mutations

Real-World Experience with CPX-351 for Secondary Acute Myeloid Leukemia: Comparison with FLAG-IDA in a Propensity Score Matching Analysis

Depletion of CD59 Inhibits the Proliferation and Survival of Acute Myeloid Leukemia Cells By Altering Lipid Raft Composition and Suppression of Raf/MEK/ERK Signaling

FLAG-IDA Plus Venetoclax in High-Risk Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia: The Princess Margaret Cancer Center Experience

Uncovering the Role of CD59 As a Novel Therapeutic Target Against High-Risk Acute Myeloid Leukemia

Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia Patients with FMS3-like Tyrosine Kinase-3 Internal Tandem Duplication (FLT3-ITD)

Final Results of the Phase Ib/II Study Evaluating Enasidenib in Combination with Venetoclax in Patients with IDH2 -Mutated Relapsed/Refractory Myeloid Malignancies

Somatic TET2 Mutations Prime the Immune System for Response to Immune Checkpoint Blockade

Outcome of ALL in Adult Patient with Down Syndrome, Single Center Experience

Thrombopoietin Receptor Signaling Promotes the Competitive Advantage of TET2 -Mutated Hematopoietic Stem and Progenitor Cells in Clonal Hematopoiesis

Metformin Treatment Abrogates the Competitive Advantage of Dnmt3a R878H HSPCs By Enhancing DNA Methylation Activity

Clinical and Biological Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (t-ALL) Following Multiple Myeloma Are Distinct in Comparison to t-ALL Following Other Cancers

Multiparameter Flow Cytometry-Based Residual Disease Analysis Identifies Intermediate-Risk AML Patients Who May Benefit from Allogeneic Hematopoietic Stem Cell Transplantation

Acute Lymphoblastic Leukemia in Patients 60 Years and Older Treated with Pediatric-Inspired Protocols, 20 Years of Follow-up

Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?

A Novel Role for PLK1 in Leukemia Stem Cell Function in Acute Myeloid Leukemia

Single Centre, Retrospective Analysis of Treatment Outcomes and Prognostic Factors in Blastic Phase Chronic Myeloid Leukemia (CML-BP) Following Systemic Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only